CH Bartlett

Abstract P2-09-10: Comprehensive gene expression biomarker analysis of CDK 4/6 and endocrine pathways from the PALOMA-2 study

RS Finn, Y Liu, M. Martín et al. · Cancer Research · 2018 · 29 citations

Medicine, Oncology, Pharmacology +17

Abstract P3-17-03: Concordance of real world progression free survival (PFS) on endocrine therapy as first line treatment for metastatic breast cancer using electronic health record with proper quality control versus conventional PFS from a phase 3 trial

CH Bartlett, Jack Mardekian, Matthew J. Cotter et al. · Cancer Research · 2018 · 11 citations

Medicine, Health Informatics, Oncology +16

Abstract OT2-01-06: Phase III study of <u>p</u>albociclib (PD-0332991) in combination with <u>e</u>ndocrine therapy (exemestane or fulvestrant) versus chemotherapy (capecitabine) in hormonal receptor (HR) positive/HER2 negative metastatic breast cancer (MBC) patients with <u>r</u>esistance to <u>a</u>romatase inhibitors. <i>“The PEARL study”</i> (GEICAM/2013-02)

M. Martín, Zsuzsanna Kahán, Eva Carrasco et al. · Cancer Research · 2017 · 10 citations

Medicine, Oncology, Pharmacology +15